Showing 1 - 6 results of 6 for search 'Martin S. Maron', query time: 0.02s Refine Results
  1. 1
    Commentary: Reoperative apical myectomy, a long run for a short slide, or a clear benefit yet to be determinedCentral Message

    Commentary: Reoperative apical myectomy, a long run for a short slide, or a clear benefit yet to be determinedCentral Message by Afshin Ehsan, MD, Martin S. Maron, MD

    Published 2022-02-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Evidence of Declining Mortality Trends for Hypertrophic Cardiomyopathy in the United States and the Impact of the COVID‐19 Pandemic

    Evidence of Declining Mortality Trends for Hypertrophic Cardiomyopathy in the United States and the Impact of the COVID‐19 Pandemic by Ahmed Sayed, Barry J. Maron, Ethan J. Rowin, Martin S. Maron

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Single Cell Transcriptomic Profiling of MYBPC3‐Associated Hypertrophic Cardiomyopathy Across Species Reveals Conservation of Biological Process But Not Gene Expression

    Single Cell Transcriptomic Profiling of MYBPC3‐Associated Hypertrophic Cardiomyopathy Across Species Reveals Conservation of Biological Process But Not Gene Expression by Samia A. Ali, Gayani Perera, Jason Laird, Rebecca Batorsky, Martin S. Maron, Victor N. Rivas, Joshua A. Stern, Samantha Harris, Michael T. Chin

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5 Years

    Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5 Years by Daniele Massera, Mark V. Sherrid, Elizabeth Adlestein, Nadia Bokhari, Isabel C. Alvarez, Woon Y. Wu, Maria C. Reuter, Martin S. Maron, Barry J. Maron, Ethan J. Rowin

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy

    Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy by Bryton J. Davis, Hailey Volk, Olives Nguyen, Daniel Kamna, Hongya Chen, Roberto Barriales‐Villa, Pablo Garcia‐Pavia, Iacopo Olivotto, Anjali T. Owens, Caroline J. Coats, Theodore P. Abraham, Scott D. Solomon, Martin S. Maron, Ahmad Masri

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM

    Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM by Caroline J. Coats, Ahmad Masri, Michael E. Nassif, Roberto Barriales‐Villa, Michael Arad, Nuno Cardim, Lubna Choudhury, Brian Claggett, Hans‐Dirk Düngen, Pablo Garcia‐Pavia, Albert A. Hagège, James L. Januzzi, Matthew M. Y. Lee, Gregory D. Lewis, Chang‐Sheng Ma, Martin S. Maron, Zi Michael Miao, Michelle Michels, Iacopo Olivotto, Artur Oreziak, Anjali T. Owens, John A. Spertus, Scott D. Solomon, Jacob Tfelt‐Hansen, Marion van Sinttruije, Josef Veselka, Hugh Watkins, Daniel L. Jacoby, Polina German, Stephen B. Heitner, Stuart Kupfer, Justin D. Lutz, Fady I. Malik, Lisa Meng, Amy Wohltman, Theodore P. Abraham

    Published 2024-08-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: